Hints and tips:
Related Special Reports
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...Zealand’s products in development will have to compete with the popular Wegovy and Zepbound drugs already on the market and made by Novo Nordisk and Eli Lilly respectively, which suppress appetite....
...Martin Holst Lange, executive vice-president of development at Novo Nordisk, said preventing obesity would be the “holy grail”....
...He said Novo Nordisk was facing a “similar challenge” as some of the companies selling advanced therapies....
...Holdings, the parent company of Novo Nordisk....
...Martin Holst Lange, head of development at Novo Nordisk, said that Cardior’s drug had the “potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people...
...“Approximately 40% of people with type 2 diabetes have chronic kidney disease,” said Martin Holst Lange, the company’s executive vice-president for development....
...“It’s unlikely we have high amounts of spare capacity [in the market].”Novo Nordisk, Eli Lilly, and Pfizer all have weight-loss pills under development, which could solve the fill-finish supply issues....
...Danish drugmaker Novo Nordisk has been “surprised” by the readiness of European consumers to pay for weight-loss drugs from their own pockets, as the region’s largest company invests in new supply to meet...
...Eli Lilly, maker of Mounjaro and the recently approved Zepbound, and Novo Nordisk have so far dominated the sector....
...Wegovy has been on sale since only 2021 and Zepbound was approved just five months ago, but Novo Nordisk and Eli Lilly are already leading the development of the next generation of weight-loss drugs....
...Lex has been watching the development of this market closely....
...The US Food and Drug Administration says there is a shortage of Novo Nordisk’s and Eli Lilly’s diabetes drugs, while Belgium has banned the off-label use of Novo Nordisk’s diabetes drug for obesity treatments...
...Shortly after Jørgensen joined the company’s development committee but before he became chief executive, Novo needed to decide whether to invest more in trials for an earlier obesity drug....
...Like Novo Nordisk’s Wegovy and Ozempic, Viking’s VK2735 mimics the GLP-1 hormone that can suppress appetite....
...Under the latest deals, Novo Nordisk will reimburse research and development costs for Omega Therapeutics, a developer of messenger RNA treatments, which is trying to develop weight-loss drugs that work...
...As such, he helped lead the development of the drugs that have transformed the company’s fortunes....
...Martin Holst Lange, executive vice-president of development at Novo Nordisk, said new data showed in more detail how the drug was “incredibly powerful” in tackling cardiovascular risk....
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
...Eli Lilly also reported positive phase II results for the treatment of MASH this month, while Novo Nordisk’s Wegovy is in late stage trials for the disease area....
...Jeff Emmick, Eli Lilly’s senior vice-president of product development, said that while as many as 80mn US adults may suffer from obstructive sleep apnoea, about a quarter of whom face more serious symptoms...
...Currently there are more than 100 GLP-1 pipeline drugs under development. These locally-made drugs are not far off hitting the market....
...Jørgensen said many of Novo’s new medicines were already being developed in the US at its Cambridge, Massachusetts, campus near Boston. “When we start clinical development, we start in the US....
...Martin Holst Lange, head of development at Novo Nordisk, said the potential of the ultrasound technology was “compelling”....
...Talon wants to diversify the economy and put culture and tourism as major pillars of development next to agriculture.”...
International Edition